RxDoctor Payments DataLook up a doctor →

Farid Roman, MD

Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1851366355

Payments from drug & device makers

$61,658in general payments, 2019–2025

Across 1,035 payments — averaging $59.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$22K
  • AstraZeneca$19K
  • Boehringer Ingelheim$5K
  • Lilly USA, LLC$4K
  • Abbott$3K
  • Medtronic$2K
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$3,3755%
  • Speaking & faculty fees$37,28960%
  • Travel & lodging$2,9955%
  • Food & beverage$17,95329%
  • Education$460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk206$21,655
AstraZeneca(2 entities)136$18,936
Boehringer Ingelheim31$5,261
Lilly USA, LLC59$4,369
Abbott153$2,926
Medtronic(3 entities)36$1,666
Dexcom, Inc.56$820
Insulet Corporation62$634
Senseonics, Incorporated5$450
Sanofi-aventis U.S. LLC22$426
Merck20$288
Johnson & Johnson(2 entities)15$240
AbbVie18$237
Amgen(2 entities)12$219
Amarin Pharma, Inc.14$205
Corcept Therapeutics9$181
Xeris Pharmaceuticals, Inc.8$175
Gilead10$161
Sunovion Pharmaceuticals Inc.17$155
Bayer8$139
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$130
Radius Health, Inc.6$119
Akcea Therapeutics, Inc.6$112
Ascensia Diabetes Care US Inc.5$111
Sanofi6$105
SK Life Science, Inc.6$103
UCB, Inc.6$94
Mannkind Corporation5$92
BETA Bionics, Inc.7$90
Argenx US, Inc.3$87
Antares Pharma, Inc.5$87
Grifols USA, LLC4$72
Takeda Pharmaceuticals U.S.A., Inc.4$72
IBSA Pharma Inc.4$64
Acadia Pharmaceuticals Inc3$62
Biogen3$60
Novartis3$59
Valeritas, Inc.2$58
GE HealthCare3$57
Ironwood Pharmaceuticals, Inc4$55
Biohaven Pharmaceuticals, Inc.3$53
Lundbeck LLC3$52
Kyowa Kirin, Inc.3$47
Sumitomo Pharma America, Inc.2$46
Neurelis, Inc.2$43
Intuity Medical Inc2$43
BD3$40
EMD Serono, Inc.2$39
Verity Pharmaceuticals Inc.1$32
Tandem Diabetes Care, Inc.2$31
Upsher-smith Laboratories LLC2$31
Braintree Laboratories, Inc.2$30
Intercept Pharmaceuticals, Inc.2$28
Teva Pharmaceuticals USA, Inc.1$27
Biohaven Pharmaceutical Holding Company Ltd.1$25
Eisai Inc.1$25
Vanda Pharmaceuticals Inc.1$23
Corium, LLC1$22
Catalyst Pharmaceuticals, Inc.1$21
Supernus Pharmaceuticals, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,658 in reported general payments places this provider in the 85th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

See all endocrinology, diabetes & metabolism providers in Missouri

Medicare billing

Part B allowed, 2024
$73,897
Medicare patients
430
Services billed
2,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide594$867,106
JardianceEmpagliflozin372$450,986
FarxigaDapagliflozin Propanediol411$400,105
TrulicityDulaglutide171$261,293
MounjaroTirzepatide203$250,533
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7104$133,209
JanuviaSitagliptin Phosphate95$113,100
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt54$106,140
Tresiba Flextouch U-200Insulin Degludec62$71,308
Tresiba Flextouch U-100Insulin Degludec116$70,003
Humulin R U-500 KwikpenInsulin Regular, Human39$69,956
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog74$56,156
Humalog Kwikpen U-100Insulin Lispro172$51,974
Fiasp FlextouchInsulin Aspart (Niacinamide)65$47,275
Humulin R U-500Insulin Regular, Human13$45,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog, Xultophy 100-3.6$21,655$945,150703 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$4,369$542,223439 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$5,261$509,502427 claims
AstraZenecaFarxiga$18,936$400,105411 claims
MerckJanuvia, Janumet$288$144,292113 claims
Radius Health, Inc.Tymlos$119$32,19612 claims
AmgenProlia$219$29,77717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

Other endocrinology, diabetes & metabolism in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →